HERA Project, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2025, in Chicago, Illinois, USA, by the GC06 Group on New Cancer Therapies from IMIBIC.
The HERA Project explores postpartum breast cancer (PPBC), a distinct and aggressive subtype of breast cancer diagnosed within ten years after childbirth. Recognized for its poor prognosis and unique molecular features, PPBC currently lacks reliable, non-invasive biomarkers for early detection. To address this gap, HERA has established the world’s largest breast milk biobank, with over 3,000 samples collected across eight Andalusian hospitals. By applying multi-omics analyses (genomic, epigenomic, proteomic, and viromic) to breast milk, the project seeks to identify molecular drivers and predictive biomarkers of PPBC. This innovative approach aims to enable early detection through a simple, non-invasive test, ultimately improving outcomes for young women and advancing precision oncology.
The poster was designed to combine clarity and visual impact. A central, bold question was placed at the top to immediately draw attention and underline the main objective of the study. The content avoids excessive text, instead relying on explanatory visuals and diagrams to convey complex information in an accessible way. The layout maintains a clean and consistent aesthetic, and includes a clear space for acknowledgments and contact details to encourage engagement and collaboration.
